Submitted by reuters8361 in business
Germany's drug regulator BfArM is considering an export ban on Novo Nordisk's <a href="https://www.reuters.com/markets/companies/NOVOb.CO" target="_blank">(NOVOb.CO)</a> diabetes drug Ozempic, which is in high demand for its weight-loss benefits, as European …